Sastasundar Ventures Ltd
Incorporated in 1989, Sastasundar Ventures Ltd is in the business of digital network of healthcare and portfolio management services[1]
- Market Cap ₹ 912 Cr.
- Current Price ₹ 286
- High / Low ₹ 383 / 205
- Stock P/E
- Book Value ₹ 214
- Dividend Yield 0.00 %
- ROCE -1.33 %
- ROE 4.63 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's median sales growth is 37.1% of last 10 years
- Company's working capital requirements have reduced from 66.1 days to 47.0 days
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.12% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 | 52 | 89 | 135 | 162 | 222 | 388 | 551 | 1,798 | 1,060 | 1,432 | 1,159 | 1,167 | |
| 35 | 62 | 116 | 155 | 175 | 255 | 440 | 561 | 684 | 1,168 | 1,456 | 1,177 | 1,232 | |
| Operating Profit | -4 | -10 | -28 | -20 | -13 | -33 | -52 | -10 | 1,114 | -107 | -24 | -19 | -65 |
| OPM % | -15% | -19% | -31% | -15% | -8% | -15% | -13% | -2% | 62% | -10% | -2% | -2% | -6% |
| 0 | 2 | -0 | 2 | 7 | 0 | 1 | 1 | 3 | -5 | 4 | -179 | 39 | |
| Interest | 1 | 1 | 2 | 3 | 1 | 3 | 1 | 3 | 3 | 2 | 1 | 0 | 0 |
| Depreciation | 2 | 6 | 7 | 7 | 6 | 6 | 5 | 4 | 4 | 8 | 9 | 6 | 5 |
| Profit before tax | -7 | -15 | -37 | -28 | -12 | -42 | -58 | -16 | 1,109 | -122 | -30 | -204 | -32 |
| Tax % | -5% | -0% | -1% | 2% | 19% | 3% | -9% | 4% | 22% | -19% | -119% | -34% | |
| -6 | -15 | -37 | -29 | -15 | -43 | -52 | -17 | 865 | -99 | 6 | -134 | -9 | |
| EPS in Rs | -2.03 | -4.68 | -11.51 | -9.00 | -3.73 | -11.81 | -12.19 | -3.27 | 197.05 | -22.70 | 2.79 | -28.66 | -0.64 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 24% |
| 3 Years: | -14% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 23% |
| 3 Years: | 43% |
| TTM: | -102% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 17% |
| 3 Years: | -2% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -2% |
| 3 Years: | -1% |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 |
| Reserves | 238 | 223 | 186 | 163 | 144 | 111 | 178 | 168 | 795 | 722 | 731 | 638 | 650 |
| 0 | 5 | 19 | 21 | 12 | 2 | 8 | 12 | 2 | 9 | 4 | 1 | 5 | |
| 39 | 22 | 20 | 35 | 48 | 86 | 98 | 80 | 449 | 441 | 383 | 300 | 321 | |
| Total Liabilities | 309 | 281 | 256 | 251 | 235 | 230 | 316 | 293 | 1,278 | 1,204 | 1,149 | 970 | 1,008 |
| 117 | 137 | 126 | 125 | 117 | 116 | 114 | 110 | 93 | 107 | 110 | 102 | 117 | |
| CWIP | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 10 | 1 |
| Investments | 41 | 22 | 10 | 17 | 46 | 36 | 56 | 43 | 666 | 513 | 676 | 575 | 633 |
| 151 | 119 | 120 | 110 | 71 | 77 | 146 | 139 | 518 | 583 | 363 | 283 | 257 | |
| Total Assets | 309 | 281 | 256 | 251 | 235 | 230 | 316 | 293 | 1,278 | 1,204 | 1,149 | 970 | 1,008 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36 | -12 | -12 | -2 | -49 | -30 | -69 | -31 | -207 | -112 | 36 | -17 | |
| -42 | 7 | -1 | 4 | 15 | -2 | -22 | 21 | 220 | 133 | -34 | -1 | |
| -3 | 4 | 13 | 5 | 33 | 26 | 103 | 4 | -11 | -2 | -2 | -0 | |
| Net Cash Flow | -10 | -1 | -0 | 7 | -2 | -6 | 11 | -5 | 1 | 19 | -0 | -19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 169 | 87 | 34 | 52 | 9 | 13 | 14 | 9 | 4 | 12 | 9 | 3 |
| Inventory Days | 337 | 91 | 80 | 73 | 59 | 77 | 57 | 71 | 69 | 34 | 40 | |
| Days Payable | 165 | 38 | 69 | 24 | 26 | 50 | 29 | 21 | 22 | 13 | 21 | |
| Cash Conversion Cycle | 169 | 259 | 87 | 62 | 58 | 46 | 41 | 38 | 55 | 59 | 31 | 22 |
| Working Capital Days | 441 | 344 | 182 | 49 | 61 | 61 | 54 | 44 | 46 | 93 | 58 | 47 |
| ROCE % | -2% | -6% | -14% | -12% | -8% | -19% | -25% | -6% | -7% | -11% | -3% | -1% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 1d
-
Results - Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025
1d - Board approved unaudited standalone and consolidated results for quarter/half year ended 30 Sep 2025; consolidated income Rs.63,054.37 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2025
1d - Board approved Q2/H1 Sep 30, 2025 results; consolidated loss ~Rs1,255 lakh; SHBL buy-back Rs10,000 lakh.
-
Disclosure Under Reg 30 Of SEBI (LODR) Reg, 2015 - Update On The Buy-Back Proposal By Sastasundar Healthbuddy Limited, Unlisted Material Subsidiary Of The Company
11 Nov - SHBL bought 20,27,534 shares from Mitsubishi at Rs.493.21 each; consideration ≤ Rs.100,00,00,044; parent stake rises to 78.89%
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
10 Nov - Of Schedule of the Earnings Conference Call for Q2 and half year of FY26 and registration Link thereof
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Concalls
-
Nov 2025TranscriptNotesPPT
-
Aug 2025TranscriptNotesPPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
Business Overview:[1][2][3]
SSVL, a Core Investment Company (CIC), operates through multiple subsidiaries and offers a digital platform for pharmacy, wellness, and diagnostics, serving both B2B and B2C segments with person-centric healthcare solutions.